CABA CABA
Company Profile ↓Company Overview
CABA (CABA) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +80.67% |
| 6 Months: | +4.63% |
| 3 Months: | -34.70% |
| 1 Month: | -12.58% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.86 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 34.7% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -3.08M | -3.99M | -3.80M | -5.03M | -7.89M | -8.19M | -8.42M | -9.71M | -11.14M | -11.56M | -13.00M | -13.06M | -11.78M | -16.96M | -15.89M | -18.67M | -28.03M | -30.28M | -33.05M | -37.14M | -45.91M | -46.59M | -44.30M |
| Net Income | -9.28M | -3.53M | -3.36M | -4.65M | -7.49M | -8.15M | -8.39M | -9.70M | -11.14M | -11.56M | -12.95M | -12.91M | -11.43M | -15.85M | -14.49M | -16.45M | -25.05M | -27.60M | -30.63M | -35.94M | -45.13M | -44.87M | -43.52M |
| Diluted EPS | - | - | -1.87 | -2.17 | - | - | - | - | -0.45 | -0.45 | -0.45 | -0.45 | -0.39 | -0.45 | -0.37 | -0.37 | -0.51 | -0.56 | -0.62 | -0.71 | -0.73 | -0.44 | -0.39 |
| R&D Expense | 2.59M | 2.76M | 2.66M | 3.22M | 4.62M | 5.33M | 5.65M | 6.56M | 7.85M | 8.17M | 9.17M | 9.51M | 8.22M | 12.44M | 11.80M | 13.79M | 21.95M | 23.43M | 26.29M | 29.02M | 37.64M | 39.82M | 37.35M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Income | -6.19M | -18.68M | -33.83M | -46.31M | -54.14M | -74.66M | -125.14M | -172.24M |
| Net Income | -12.20M | -16.94M | -33.34M | -46.29M | -52.98M | -67.67M | -115.86M | -167.86M |
| Diluted EPS | - | - | - | -1.80 | -1.81 | -1.65 | -2.34 | -2.10 |
| R&D Expense | 4.47M | 11.67M | 21.38M | 32.49M | 39.30M | 55.42M | 97.20M | 142.67M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 34.17M | 141.47M | 114.72M | 126.34M | 116.97M | 253.65M | 185.05M | 165.08M |
| Total Equity | -249.00K | -10.69M | 138.32M | 109.54M | 117.96M | 104.52M | 236.20M | 152.34M | 112.05M |
| Cash & Equivalents | - | 33.02M | 136.20M | 101.43M | 122.22M | 81.61M | 193.24M | 163.96M | 82.98M |
| Total Liabilities | - | - | - | - | 8.38M | 12.45M | 17.45M | 32.71M | 53.03M |
| Current Liabilities | - | 943.00K | 3.15M | 5.18M | 8.38M | 9.49M | 15.99M | 27.09M | 50.15M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.66M | -16.05M | -26.77M | -34.11M | -46.38M | -53.55M | -88.22M | -131.08M |
| Investing Cash Flow | - | -693.00K | -7.98M | 6.00M | -27.22M | -22.45M | 47.29M | -50.27M |
| Financing Cash Flow | 37.68M | 119.92M | -24.00K | 48.90M | 32.98M | 187.63M | 11.68M | 100.35M |
| Capital Expenditure | - | -693.00K | -635.00K | -1.17M | -2.45M | -687.00K | -2.21M | -1.23M |
| Free Cash Flow | - | -16.74M | -27.41M | -35.27M | -48.83M | -54.24M | -90.43M | -132.31M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - |
| ROE % | 114.1% | -12.2% | -30.4% | -39.2% | -50.7% | -28.7% | -76.1% | -149.8% |
| ROCE % | -18.6% | -13.5% | -30.9% | -39.3% | -50.4% | -31.4% | -79.2% | -149.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CABA
CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxNUHJPM3M0aTRTSk5IVFJUVTVpbU0yYjFrMlhPYnVZbDVtRGdBQ093NzlSZkgzY05ocldCR1VxRDZPT1ViLVQyeUNnSFh1VlBQdVBzM3p1ZGZEUGZqRUtCYWo2QnlZUU5wUU1BNV9ZWE84X3pLU0VGaVltRHVLUE5zZm5OZmoxcjE5TzBXTj…
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPbllIYm96WExycGpMaXRiSks2bUN4bU9MYmM0azA3ZXRCYzVPd1dwR3pEbUpZM2dySG5jSkpILWtQcXEzYy1ic3JoSXFmalVrcHl4U01PbWNTekpQTllMbnFDUzhBR3pNYXZYa2pkX2lBZm9qRHdoTjJadUUwYmxEVnJLdGNCYW9WTm9tZi…
Cabaletta Bio: The Market Sold The EULAR News, I'm Buying (NASDAQ:CABA) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNek1TUk1CS2xKR0FlXzNDekVCWWdfbUMzemVhbEFRcXhrUkNyaTlzTDBubFJlcWQ5dkVlaFJaOVdlM01JNm9lR1JOdnpHNnpxZEVyNmZPYlgxVnEyUnF6ODJnV1VCSGJocjQ2c3E2aW03a3lSanFranNUazd3eURLQXVuSzVOVmhrZmpsem…
BlackRock, Inc. Boosts Cabaletta Bio (CABA) Stake with Significa - GuruFocus
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQVk1JMndOWDJpTUxqNU1rZnlYallkVHpwc0M0LXBjWjB0UVlJdXMtb2xnQjB6RERtand0Rm56dVp3YUNIb3JKczh1U19zMUYyVXJwSDFibllKVExlalpOMWo2bEJWdkl5MHZ3RGo3SVBzN3VXdkJZTTk4V1BwUlFjczNSWFdZbmVvVkpNcj…
Cabaletta Bio (CABA) to Post Earnings on Thursday - MarketBeat
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPUTZwYmg2QmV0d0FQVW9xMGI5XzlJLUw3ZTZ1SkQxRVp3dk1EVlR0aHBXRkItWWNSNFBVZ3NVUlQtZUtSOF9GS3lDelY1R0dvNGo0OWY0Q2dEZHpOR3g5UXVORS10aUdpTWRNZHlGS0tNdDFZSFJONFBYckJndmVVMDJ4c1RmbENocGVuR2…
BlackRock (CABA) discloses 9.6M Cabaletta Bio shares under sole control - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNeGJNazRxRzJxN042UzRObDdvOXBMbkJsRTNkUDlhUS1wMnNsM0NLZngzeE5IX0o0eldXM1JkTXJ3QklJdzV0c1JycWRoVGgtZThDWmRTdXZvODV2bUdITDBpdUpuZkQ0dmNSbEtySXNfRWpyeWdvWGd2eFJDTGdGRzVHWnhoSDdDR1dsUz…
CABA — Frequently Asked Questions
What is the current share price of CABA?
As of 2026-08-05 17:25 PDT, CABA trades at $2.71 on NASDAQ/NYSE. Its 52-week range is $1.33 to $4.15.
What is the P/E ratio of CABA?
CABA trades at a trailing price-to-earnings (P/E) ratio of -1.29.
What is the return on equity (ROE) of CABA?
CABA has a return on equity (ROE) of -149.80%. Its return on capital employed (ROCE) is -149.87%.
Is CABA a good stock to buy?
This page provides a data-driven analysis of CABA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.